Camurus AB
STO:CAMX

Watchlist Manager
Camurus AB Logo
Camurus AB
STO:CAMX
Watchlist
Price: 589 SEK 0.17% Market Closed
Market Cap: 34.7B SEK

Relative Value

The Relative Value of one CAMX stock under the Base Case scenario is 1 432.44 SEK. Compared to the current market price of 589 SEK, Camurus AB is Undervalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CAMX Relative Value
Base Case
1 432.44 SEK
Undervaluation 59%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
42
vs Industry
8
Median 3Y
16
Median 5Y
17.4
Industry
2.4
Forward
11.7
vs History
26
vs Industry
4
Median 3Y
77.7
Median 5Y
37.6
Industry
20.6
Forward
35.5
vs History
22
vs Industry
4
Median 3Y
81.2
Median 5Y
27.8
Industry
15.5
vs History
17
vs Industry
4
Median 3Y
56
Median 5Y
-15.4
Industry
23
vs History
84
vs Industry
5
Median 3Y
12.2
Median 5Y
12.2
Industry
1.9
vs History
44
vs Industry
9
Median 3Y
14.8
Median 5Y
16.3
Industry
2.5
Forward
10.7
vs History
49
vs Industry
10
Median 3Y
16.8
Median 5Y
18.3
Industry
4.9
vs History
31
vs Industry
5
Median 3Y
65.6
Median 5Y
30.1
Industry
12.6
Forward
26.5
vs History
26
vs Industry
5
Median 3Y
63.8
Median 5Y
28.1
Industry
15.7
Forward
26.9
vs History
25
vs Industry
5
Median 3Y
77.9
Median 5Y
25.9
Industry
14
vs History
20
vs Industry
5
Median 3Y
80.4
Median 5Y
26.2
Industry
17.7
vs History
19
vs Industry
2
Median 3Y
26.3
Median 5Y
19.5
Industry
1.8

Multiples Across Competitors

CAMX Competitors Multiples
Camurus AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Camurus AB
STO:CAMX
34.7B SEK 18.6 81 64.7 66.7
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
SE
Camurus AB
STO:CAMX
Average P/E: 32.3
81
79%
1
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBITDA: 400.3
64.7
82%
0.8
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Camurus AB
STO:CAMX
Average EV/EBIT: 1 703.6
66.7
92%
0.7
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4